Acute Pancreatitis Severity Scoring And The HM17 Bedside Approach

Acute pancreatitis can shift from a painful but self-limiting illness to respiratory failure, shock, renal injury or infected necrosis within a short period. For hospitalists, the early task is therefore less about naming a score than recognising which patients need closer observation, repeated assessment and timely escalation.

At Hospital Medicine 2017, held at Mandalay Bay in Las Vegas from 1–4 May, the practical emphasis was on a rapid, usable bedside assessment. The tool most consistent with that approach was the BISAP score, or Bedside Index for Severity in Acute Pancreatitis. It was favoured as an early risk-stratification aid because it can be calculated during the first 24 hours without the extensive data collection required by some older systems.

What The BISAP Score Measures

BISAP uses five findings gathered during the first day of admission. These are blood urea nitrogen above 25 mg/dL, impaired mental status, systemic inflammatory response syndrome, age over 60 years and pleural effusion. Each item contributes one point, producing a score from 0 to 5.

The score is useful because it combines clinical examination, basic biochemistry and an accessible imaging finding. A rising urea level may indicate reduced circulating volume or significant physiological stress, while confusion and SIRS signal systemic involvement. Pleural effusion can suggest a more substantial inflammatory response, although it should be interpreted alongside the patient’s respiratory status and chest imaging.

BISAP is a triage tool rather than a definitive forecast. A low score does not remove the need for fluid assessment, analgesia, observation and repeat examination. A high or increasing score should prompt senior review and consideration of a high-dependency or intensive care setting, depending on the patient’s trajectory and local capacity.

Why HM17 Favoured A Practical Bedside Tool

Ranson’s criteria have historical value, but they require information at admission and again at 48 hours. That delay limits their usefulness when clinicians must decide where a patient should be managed during the first few hours. APACHE II is comprehensive and can be repeated, yet it is more cumbersome and depends on data that may not be readily available in a general ward.

BISAP fits the workflow of an acute medical unit. A hospitalist can calculate it from the initial history, observations, routine pathology and chest imaging, then repeat the clinical assessment as the illness evolves. This is especially relevant in Australian hospitals, where a patient may first arrive at a regional emergency department before transfer to a tertiary service in Brisbane, Perth or Melbourne.

The score also supports communication. Saying that a patient has a BISAP of 3, worsening oxygen requirements and rising urea gives the admitting team a concise summary of risk. It does not replace clinical judgement, but it helps teams identify a deteriorating pattern before organ failure becomes unmistakable.

Comparing Common Severity Assessment Tools

No scoring system should be used in isolation. Revised Atlanta classification remains important because it defines severity through organ failure and local complications, while scoring systems estimate the likelihood of a complicated course. The following comparison explains why BISAP was a sensible HM17 recommendation for early hospitalist practice.

In Australia, routine pathology reporting may use mmol/L rather than the conventional US units used in some educational materials. Clinicians should interpret the local laboratory’s reference range and convert values carefully when applying published thresholds. This is a small operational detail, yet it matters when a numerical score influences escalation.

Using The Score Alongside Clinical Assessment

A BISAP calculation should sit within an initial ABCDE review. Hypotension, tachypnoea, hypoxaemia, oliguria, increasing abdominal distension or altered consciousness may indicate serious disease regardless of the numerical result. Persistent organ failure lasting more than 48 hours is central to severe acute pancreatitis under the revised Atlanta framework.

Fluid management requires particular care. Early intravenous crystalloid is often appropriate when there is hypovolaemia, but excessive fluid administration can worsen pulmonary oedema, especially in older people or those with cardiac, renal or respiratory disease. A patient in Adelaide with chronic kidney disease may need a very different fluid strategy from a previously well adult with vomiting and clear volume depletion.

The same principle applies to imaging. Contrast-enhanced CT is not automatically required at presentation when the diagnosis is clear and there is no evidence of complication. Ultrasound remains valuable for gallstones and biliary dilation. For practical bedside guidance on focused assessment, the HM17 resource on point-of-care ultrasound provides relevant context, although ultrasound itself does not replace formal severity scoring.

Applying BISAP In Australian Hospitals

Australian practice includes substantial variation between metropolitan tertiary hospitals, district hospitals and remote services. A patient in Darwin or rural New South Wales may require early consultation with a retrieval service if respiratory or circulatory support is developing. In that setting, a documented BISAP score can support a structured referral, but the retrieval decision must be based on current physiology, available staffing and the anticipated need for organ support.

The score should be recorded with the time of assessment and the values used. Repeating it after a clinical change is more informative than treating the first calculation as permanent. Important associated findings include urine output, oxygen requirement, haematocrit, creatinine, calcium, glucose, lactate where indicated and the presence of systemic inflammatory response.

Useful bedside actions include:

• Calculate BISAP during the first 24 hours and document each component.
• Repeat observations, fluid balance and renal assessment rather than relying on the initial score.
• Escalate early for hypoxaemia, hypotension, confusion, oliguria or persistent organ failure.
• Investigate gallstone disease, alcohol exposure, hypertriglyceridaemia, medicines and anatomical causes.
• Use local pathways, senior advice and intensive care criteria when the patient’s condition is worsening.

Australian clinicians should also consider local antimicrobial stewardship expectations. Prophylactic antibiotics are not routinely indicated for uncomplicated sterile pancreatitis, while suspected cholangitis, infected necrosis or another documented infection requires a separate diagnostic and treatment pathway. Early gastroenterology, surgery, radiology and intensive care involvement may be more valuable than adding multiple scores.

Where The Recommendation Fits Today

The significance of the HM17 recommendation was its emphasis on usability. BISAP offered a transparent way to identify risk at the bedside without waiting 48 hours or assembling a complex physiological dataset. It was particularly suitable for hospital medicine, where clinicians manage the transition from emergency assessment to ward care and must recognise deterioration early.

The tool should still be interpreted in the context of the cause and the patient’s baseline health. Gallstone pancreatitis with jaundice may require urgent biliary evaluation; severe alcohol-related disease may be accompanied by nutritional and withdrawal concerns; and pancreatitis after a procedure may require a different specialist response. Age, frailty and comorbidities can also make a modest score clinically significant.

The broader HM17 educational programme connected evidence, practical workflows and professional learning for hospitalists. Conference materials and related resources remain available through the HM17 conference site, offering historical context for the meeting’s focus on bedside decisions, patient safety and coordinated hospital care.

BISAP is best understood as an early warning framework, not a substitute for diagnosis, monitoring or treatment. Its value comes from combining a quick numerical summary with repeated examination and timely escalation. The key point to remember is that HM17’s practical choice was BISAP for early risk assessment, used alongside clinical judgement and the revised Atlanta definition of severe disease.